These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
158 related articles for article (PubMed ID: 37005318)
1. Safety of SGLT2 Inhibitors in Three Chronic Diseases. Ge S; Liu R; Mao Y; Geng C; Wang H; Song K; Tian QB Int Heart J; 2023; 64(2):246-251. PubMed ID: 37005318 [TBL] [Abstract][Full Text] [Related]
2. Safety of four SGLT2 inhibitors in three chronic diseases: A meta-analysis of large randomized trials of SGLT2 inhibitors. Qiu M; Ding LL; Zhang M; Zhou HR Diab Vasc Dis Res; 2021; 18(2):14791641211011016. PubMed ID: 33887983 [TBL] [Abstract][Full Text] [Related]
3. Potential Safety Issues with Use of Sodium-Glucose Cotransporter 2 Inhibitors, Particularly in People with Type 2 Diabetes and Chronic Kidney Disease. Milder TY; Stocker SL; Day RO; Greenfield JR Drug Saf; 2020 Dec; 43(12):1211-1221. PubMed ID: 33095409 [TBL] [Abstract][Full Text] [Related]
4. Safety of Sodium-Glucose Co-Transporter 2 Inhibitors. McGill JB; Subramanian S Am J Cardiol; 2019 Dec; 124 Suppl 1():S45-S52. PubMed ID: 31741440 [TBL] [Abstract][Full Text] [Related]
5. Safety of sodium-glucose cotransporter 2 inhibitors in elderly patients with type 2 diabetes: A meta-analysis of randomized controlled trials. Rigato M; Fadini GP; Avogaro A Diabetes Obes Metab; 2023 Oct; 25(10):2963-2969. PubMed ID: 37402697 [TBL] [Abstract][Full Text] [Related]
6. SGLT2 Inhibitors and Safety in Older Patients. Pollack R; Cahn A Heart Fail Clin; 2022 Oct; 18(4):635-643. PubMed ID: 36216492 [TBL] [Abstract][Full Text] [Related]
7. Comparative safety of sodium-glucose co-transporter 2 inhibitors in elderly patients with type 2 diabetes mellitus and diabetic kidney disease: a systematic review and meta-analysis. Liu Y; An C; Liu P; Yang F; Zhao Q Ren Fail; 2023 Dec; 45(1):2217287. PubMed ID: 37246403 [TBL] [Abstract][Full Text] [Related]
8. Adverse Events of Sodium-Glucose Cotransporter-2 Inhibitors in Chronic Kidney Disease: A Retrospective Chart Review. Choi H; Nguyen LA; Wan J; Milani H; McGill K; Park J Perm J; 2021 May; 25():. PubMed ID: 33970086 [TBL] [Abstract][Full Text] [Related]
9. Cardiovascular and renal efficacy and safety of sodium-glucose cotransporter-2 inhibitors in patients without diabetes: a systematic review and meta-analysis of randomised placebo-controlled trials. Tsai WC; Hsu SP; Chiu YL; Yang JY; Pai MF; Ko MJ; Tu YK; Hung KY; Chien KL; Peng YS; Wu HY BMJ Open; 2022 Oct; 12(10):e060655. PubMed ID: 36241355 [TBL] [Abstract][Full Text] [Related]
10. Clinical Adverse Events Associated with Sodium-Glucose Cotransporter 2 Inhibitors: A Meta-Analysis Involving 10 Randomized Clinical Trials and 71 553 Individuals. Lin DS; Lee JK; Chen WJ J Clin Endocrinol Metab; 2021 Jun; 106(7):2133-2145. PubMed ID: 33895840 [TBL] [Abstract][Full Text] [Related]
11. Acute Kidney Injury Events in Patients With Type 2 Diabetes Using SGLT2 Inhibitors Versus Other Glucose-Lowering Drugs: A Retrospective Cohort Study. Rampersad C; Kraut E; Whitlock RH; Komenda P; Woo V; Rigatto C; Tangri N Am J Kidney Dis; 2020 Oct; 76(4):471-479.e1. PubMed ID: 32464161 [TBL] [Abstract][Full Text] [Related]
12. Effects of sodium-glucose cotransporter-2 inhibitors and aldosterone antagonists, in addition to renin-angiotensin system antagonists, on major adverse kidney outcomes in patients with type 2 diabetes and chronic kidney disease: A systematic review and network meta-analysis. Yang S; Zhao L; Mi Y; He W Diabetes Obes Metab; 2022 Nov; 24(11):2159-2168. PubMed ID: 35712807 [TBL] [Abstract][Full Text] [Related]
13. Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: A systematic review and meta-analysis. Toyama T; Neuen BL; Jun M; Ohkuma T; Neal B; Jardine MJ; Heerspink HL; Wong MG; Ninomiya T; Wada T; Perkovic V Diabetes Obes Metab; 2019 May; 21(5):1237-1250. PubMed ID: 30697905 [TBL] [Abstract][Full Text] [Related]
14. Sodium-glucose co-transporter-2 inhibitors and the risk of diabetic ketoacidosis in patients with type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials. Liu J; Li L; Li S; Wang Y; Qin X; Deng K; Liu Y; Zou K; Sun X Diabetes Obes Metab; 2020 Sep; 22(9):1619-1627. PubMed ID: 32364674 [TBL] [Abstract][Full Text] [Related]
15. Comparative effectiveness and safety of sodium-glucose cotransporter-2 inhibitors versus metformin in patients with type 2 diabetes: An observational study using data from routine care. Fralick M; Schneeweiss S; Redelmeier DA; Razak F; Gomes T; Patorno E Diabetes Obes Metab; 2021 Oct; 23(10):2320-2328. PubMed ID: 34169619 [TBL] [Abstract][Full Text] [Related]
16. Safety of SGLT2 Inhibitors in Patients with Diabetes Mellitus. Singh M; Sharma R; Kumar A Curr Drug Saf; 2019; 14(2):87-93. PubMed ID: 30727912 [TBL] [Abstract][Full Text] [Related]
17. Comparison over Time of Adverse Drug Reactions in Diabetes Patients Treated with Sodium-Glucose Cotransporter 2 Inhibitors. Ueda M; Zenibayashi M; Yamada T; Asahara SI; Ogawa W Kobe J Med Sci; 2024 Jul; 70(3):E81-E88. PubMed ID: 39107964 [TBL] [Abstract][Full Text] [Related]
18. Dapagliflozin in patients with type 2 diabetes mellitus: A pooled analysis of safety data from phase IIb/III clinical trials. Jabbour S; Seufert J; Scheen A; Bailey CJ; Karup C; Langkilde AM Diabetes Obes Metab; 2018 Mar; 20(3):620-628. PubMed ID: 28950419 [TBL] [Abstract][Full Text] [Related]
19. The current role of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes mellitus management. Xu B; Li S; Kang B; Zhou J Cardiovasc Diabetol; 2022 May; 21(1):83. PubMed ID: 35614469 [TBL] [Abstract][Full Text] [Related]
20. Fournier Gangrene Associated With Sodium-Glucose Cotransporter-2 Inhibitors: A Review of Spontaneous Postmarketing Cases. Bersoff-Matcha SJ; Chamberlain C; Cao C; Kortepeter C; Chong WH Ann Intern Med; 2019 Jun; 170(11):764-769. PubMed ID: 31060053 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]